Back to Portfolio
Development Pre-Seed
Validose
Medication Adherence
Validose is creating a new paradigm in clinical drug adherence by integrating objective dosing technology, real-time data sharing, and personalized patient coaching to enhance clinical trial success, accelerate pharmaceutical decision-making, and improve patient outcomes.
Development Pre-Seed
Validose
Medication Adherence
Validose is creating a new paradigm in clinical drug adherence by integrating objective dosing technology, real-time data sharing, and personalized patient coaching to enhance clinical trial success, accelerate pharmaceutical decision-making, and improve patient outcomes.
Development Pre-Seed
Validose
Medication Adherence
Validose is creating a new paradigm in clinical drug adherence by integrating objective dosing technology, real-time data sharing, and personalized patient coaching to enhance clinical trial success, accelerate pharmaceutical decision-making, and improve patient outcomes.
The opportunity
Clinical leads in Biopharma need accurate dosing data; data about who is dosing, and patient compliance with the protocol, outside of the clinical setting.“Much of the FDA approval process is based on what patients say they did.” - Clinical Director, Pharma R&D
The solution
An intelligent dosing and data platform; we derive real time intelligence around drug adherence and efficacy for any drug medium, at any scale. Validose fills the key data gaps in real world evidence in patients’ lives: when, where, and how much of a given therapy is delivered.
The opportunity
Clinical leads in Biopharma need accurate dosing data; data about who is dosing, and patient compliance with the protocol, outside of the clinical setting.“Much of the FDA approval process is based on what patients say they did.” - Clinical Director, Pharma R&D
The solution
An intelligent dosing and data platform; we derive real time intelligence around drug adherence and efficacy for any drug medium, at any scale. Validose fills the key data gaps in real world evidence in patients’ lives: when, where, and how much of a given therapy is delivered.
The opportunity
Clinical leads in Biopharma need accurate dosing data; data about who is dosing, and patient compliance with the protocol, outside of the clinical setting.“Much of the FDA approval process is based on what patients say they did.” - Clinical Director, Pharma R&D
The solution
An intelligent dosing and data platform; we derive real time intelligence around drug adherence and efficacy for any drug medium, at any scale. Validose fills the key data gaps in real world evidence in patients’ lives: when, where, and how much of a given therapy is delivered.
+2.3X
Larger patient panels due to expected non-adherence
30%
Clinical trials fail
+1.7X
survival rate without any biochemical treatment
+2.3X
Larger patient panels due to expected non-adherence
30%
Clinical trials fail
+1.7X
survival rate without any biochemical treatment
+2.3X
Larger patient panels due to expected non-adherence
30%
Clinical trials fail
+1.7X
survival rate without any biochemical treatment
ARTICLES
Press
Inside New Lab, an 84,000-Square-Foot Tech Paradise in Brooklyn
Aug 8, 2016
Once a bustling shipbuilding hub, Building 128 at the Brooklyn Navy Yard has been transformed into New Lab—an 84,000-square-foot innovation center.
Press
Incubators Aren't Only for Tech Startups
May 14, 2014
When we think of incubators, tech startups often come to mind—but today’s incubators are more diverse and community-focused than ever.
Press
Re-Making Manufacturing in the United States
Mar 10, 2014
The U.S. manufacturing industry is experiencing a renaissance, shifting from traditional mass production to advanced, innovation-driven processes.
Press
Inside New Lab, an 84,000-Square-Foot Tech Paradise in Brooklyn
Aug 8, 2016
Once a bustling shipbuilding hub, Building 128 at the Brooklyn Navy Yard has been transformed into New Lab—an 84,000-square-foot innovation center.
Press
Incubators Aren't Only for Tech Startups
May 14, 2014
When we think of incubators, tech startups often come to mind—but today’s incubators are more diverse and community-focused than ever.
Press
Inside New Lab, an 84,000-Square-Foot Tech Paradise in Brooklyn
Aug 8, 2016
Once a bustling shipbuilding hub, Building 128 at the Brooklyn Navy Yard has been transformed into New Lab—an 84,000-square-foot innovation center.
Press
Incubators Aren't Only for Tech Startups
May 14, 2014
When we think of incubators, tech startups often come to mind—but today’s incubators are more diverse and community-focused than ever.
Press
Re-Making Manufacturing in the United States
Mar 10, 2014
The U.S. manufacturing industry is experiencing a renaissance, shifting from traditional mass production to advanced, innovation-driven processes.
